Defibrotide for the treatment of hepatic veno-occlusive disease in children

Pediatric Blood and Cancer

Volumn 48, Issue 7, 2007, Pages 700-704

  Bulley, Sean R ^a   Strahm, Brigitte ^a   Doyle, John ^a,b,c   Dupuis, L Lee ^a,b,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bone marrow transplant; Defibrotide; Hematopoietic progenitor cell transplant; Pediatrics; Sinusoidal obstruction syndrome; Venous occlusive disease

Indexed keywords

ACETYLCYSTEINE; AMPHOTERICIN; ANTINEOPLASTIC AGENT; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFIBROTIDE; DIURETIC AGENT; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN TOXICITY; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FATALITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; INFANT; LIVER VEIN OBSTRUCTION; MALE; MEDICAL RECORD; MYCOSIS; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIGIDITY; SIDE EFFECT; TREATMENT DURATION; WHOLE BODY RADIATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; MALE; POLYDEOXYRIBONUCLEOTIDES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248187052     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20934     Document Type: Article

References (27)

1. Kumar S, DeLeve LD, Kamath PS, et al. Hepatic veno-occlusive idsease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003;78:589-598.
2. Tack DK, Letendre L, Kamath PS, et al. Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant 2001;28:895-897.
3. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-783.
4. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - Liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
5. McCarville MB, Hoffer FA, Howard SC, et al. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: Usefulness of sonographic findings. Pediatr Radiol 2001;31:102-105.
6. Groszman RJ, Wongcharatrawee S. The hepatic venous pressure gradient: Anything worth doing should be done right. Hepatology 2004;39:280-282.
7. Shulman HM, Fisher LB, Schoch HG, et al. Venoocclusive disease of the liver after marrow transplantation: Histiologic correlates of clinical signs and symptoms. Hepatology 1994;19:1171-1180.
8. Barker CC, Butzner JD, Anderson RA, et al. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003;32:79-87.
9. Haire WD, Cavet J, Pavletic SZ. Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic stem cell transplantation. Blood 2000;96:584a.
10. Morado M, Ojeda E, Garcia-Bustos J. BMT: Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology 2000;4:505-512.
11. Reiss U, Cowan M, McMillan A, et al. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: Incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002;24:746-750.
12. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004;104:1574-1577.
13. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
14. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-744.
15. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000;111:1122-1129.
16. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-4343.
17. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33:189-195.
18. Bearman SI, Anderson GL, Mori M, et al. Venooclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-1736.
19. Dupuis LL, Najdova M, Saunders EF. Corrigendum: Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2003;31:729.
20. Yule SM, Walker D, Cole M, et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 1999;27:417-421.
21. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557-1559.
22. Abecasis MM, Conceicao Silva JP, Ferreira I, et al. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23:843-846.
23. Jenner MJ, Micallef IN, Rohatiner AZ, et al. Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. Med Oncol 2000;17:333-336.
24. Sayer HG, Will U, Schilling K, et al. Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation - Successful treatment with high-dose methylprednisolone and defibrotide. J Cancer Res Clin Oncol 2002;128:148-152.
25. Palomera L, Sola C, Domingo JM, et al. Hemorrhagic complications after treatment with defibrotide in a case of severe veno-occlusive disease [5]. Med Clin 2002;118:518-519.
26. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic propoerties, and therapeutic use in vascular disorders. Drugs 1993;45:259-294.
27. Ammann RA. Defibrotide for hepatic VOD in children: Exact statistics can help! Bone Marrow Transplant 2004;34:277-278.